Epcoritamab for Waldenstrom's Macroglobulinemia

This trial explores a new treatment called epcoritamab for individuals with Waldenstrom's macroglobulinemia (WM), a blood cancer that thickens the blood and impairs normal body function. The researchers aim to determine if epcoritamab can benefit those who have used Bruton tyrosine kinase inhibitors (BTKi) for over a year but still require better outcomes. Ideal candidates are adults with WM who have been on a BTKi, such as zanubrutinib or ibrutinib, for at least 12 months. Participants will receive epcoritamab injections over several months while continuing their current treatment. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

You will continue taking your current BTKi medication during the trial. However, if you are on certain other medications like CYP3A strong inducers or inhibitors, you may need to stop them before joining the trial. It's best to discuss your specific medications with the trial team.

Previous studies have shown that epcoritamab has a manageable safety profile for patients with Waldenstrom's macroglobulinemia (WM). Research indicates that common side effects include neutropenia, a low level of certain white blood cells, in about 15.3% of patients, and thrombocytopenia, a low platelet count, in about 11.5% of patients. These side effects are typical with cancer treatments and can usually be managed with medical care.

Epcoritamab is unique because it offers a novel approach to treating Waldenstrom's Macroglobulinemia. Unlike current treatments, which often include drugs like zanubrutinib or ibrutinib targeting specific proteins on cancer cells, epcoritamab is a bispecific antibody. This means it simultaneously binds to two different targets, enhancing the immune system's ability to recognize and destroy cancer cells. Researchers are excited about epcoritamab because its dual-targeting mechanism could potentially lead to more effective and lasting responses in patients with this condition.

In this trial, researchers will administer Epcoritamab as consolidative therapy for adults who have been receiving zanubrutinib or ibrutinib. Studies have shown that Epcoritamab can help treat certain blood cancers. Specifically, one study found that 61% of patients with relapsed B-cell lymphoma responded well to the treatment. Another study demonstrated that 95% of patients responded positively after about 15 months. Epcoritamab aids the immune system in identifying and destroying cancer cells. Although information is limited for Waldenstrom's macroglobulinemia, these results suggest it could be a promising treatment option.⁶⁷⁸⁹¹⁰